Navigation Links
Publication Confirms that EpCAM, the Target for Two of Micromet's,Product Candidates, Is Overexpressed on Cancer Stem Cells of,Certain Cancers

BETHESDA, Md., June 26, 2007 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, announced that a study published recently in the Proceedings of the National Academy of Sciences (1) supports the findings of several other studies that EpCAM (CD326), which is used as the target for Micromet's product candidates adecatumumab (MT201) and MT110, may be suitable as a target for eradication of so called "cancer stem cells" (CSCs). The other studies showed that CSCs from colon (2), breast (3), pancreatic (4) and prostate (5) cancers all express high levels of EpCAM, which, according to these studies, makes these cells particularly capable of causing tumors.

CSCs constitute a small percentage of tumor cells that have the potential to self-renew and to permanently repopulate a tumor with new cancer cells. CSCs appear to be resistant to various chemotherapies, which may be one of the key reasons why most current therapies cannot cure cancer through elimination of all tumor cells (6). Micromet scientists believe that the findings of EpCAM expression by CSCs in many cancers and of EpCAM being a frequently and highly expressed tumor-associated antigen (7, 8), supports Micromet's use of EpCAM for targeted therapeutics.

EpCAM is the target for Micromet's clinical-stage product candidate adecatumumab (MT201), a fully human monoclonal antibody being co-developed with Merck Serono. In addition, Micromet's BiTE(R) product candidate MT110, an anti-EpCAM/CD3-bispecific antibody construct, is currently in late preclinical development. Both product candidates are designed to recognize EpCAM- expressing cancer cells and to instruct cytotoxic cells of the immune system to eliminate such cancer cells.

"The 'seek and destroy' mechanism of our EpCAM-directed therapeutic drug can
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
5. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
6. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
7. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
8. Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO
9. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
10. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
11. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex

Post Your Comments:
(Date:11/20/2009)... LONDON, Nov. 20 Boston ...ced that it has received 510(k) clearance from the...rk approval to market its WallFlex® Fully Cov...nt esophageal strictures (obstructions) caused by ...le esophageal cancer. ,, (Photo: http://www....
(Date:11/20/2009)..., Pa., Nov. 20 In respo...tions why currently available medications designed...ed, ECRI Institute, an independent nonprofit organ... Finasteride for Prevention of Prostate Cancer fo...ew York Times article, " Drugs to Deter Some Canc...
(Date:11/20/2009)...Nov. 20 Soligenix, Inc. ...ny), formerly known as DOR BioPharma, Inc., a late... it has formed a consortium to develop thermostabl...y acting vaccines. Soligenix received a $9.4 milli...d Infectious Diseases (NIAID), a division of the N...
Breaking Medicine Technology:Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6Instrumentation Laboratory Announces Passion 26 Results Award Winners 57753 1Instrumentation Laboratory Announces Passion 26 Results Award Winners 57753 2Instrumentation Laboratory Announces Passion 26 Results Award Winners 57753 3Instrumentation Laboratory Announces Passion 26 Results Award Winners 57753 4Death Panel Inventor 26 Critic of Healthcare Reform Betsy McCaughey Has Close Ties to Philip Morris 3B Healthcare Industry Today Offers Complete Cove 57751 1Death Panel Inventor 26 Critic of Healthcare Reform Betsy McCaughey Has Close Ties to Philip Morris 3B Healthcare Industry Today Offers Complete Cove 57751 2Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 1Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 2
(Date:11/20/2009)... , CHICAGO, Nov. 20 ...the U.S. Food and Drug Administration (FDA) to est...ning chemicals. ,, Citing concern about the sa...ered without the benefit of professional consultat...aid that the application of chemically based tooth...
(Date:11/20/2009)... , WINSTON-SALEM, N.C., Nov. 20 /PRNewswire-USN...is on a mission to redefine what it means to be "h...nal counselor with a specialty in family counselin...e Forest University, Gladding says research shows ...ds to sadness and even depression during the holid...
(Date:11/20/2009)...editorial published online November 20 in the Jou...he exaggerated fears and hopes that often appear i...provides guidance for both the media and journals ...z, M.D., M.S., and Steven Woloshin, M.D., M.S., of...h Institute for Health Policy and Clinical Practic...
(Date:11/20/2009)...attle, Washington) November 20, 2009Emergency medi...ssess an estimated 350,000 cardiac arrests each ye...n cardiac arrest survive. Better quality cardiopu...l EMS providers may be associated with better pati...m (ROC) is the largest clinical research network t...
(Date:11/20/2009)...mers save up to one-third buying 90-day supply, st... News) -- Buying a three-month supply of prescript... one-month supply, according to a new study. , ...led for 395 drugs between 2000 and 2005, and found...tead of a one-month supply saved an average 29 per...
Breaking Medicine News(10 mins):Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2Health News:Why Holidays Don't Have To Be 'Happy' 2Health News:Promoting healthy skepticism in the news: Helping journalists get it right 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3Health News:Three-Month Supply Lowers Drug Costs 2
... field of genetics has been undergoing a revolutio...c mechanisms underlying common disorders and a hug...cific genetic disorders. // This has not onl...breakthrough has been the successful attempts of t...
...hlear implants for ears, which are done in a minim...e following the traditional way. Researchers from ...sent this research finding // at the 109th Annual ... scalp flap, mastoidectomy (a surgical removal of ...
... investigations suggest that treating the problem ...ren join school, can go a long way in curing the c...me out in the latest // edition of BMJ. About...cessary, but evidence to support this is currently...
...earchers from the University of Texas, M.D. Anders... on mutation or damage leads to development of col...efect in this gene leads to // development of colo...ancer. The study was conducted in 95 colorec...
...ox is a wrinkle control cream and a potent neuroto...wrinkles. The product is derived form a bacteria, ...// It is really surprising to note that this ...nction, minute changes that underlie memory and le...
...ing to counter the threat posed by new virus-induc...s, a city-based institute has launched a course of... Institute of // Biotechnology and Bioinformatics ...course is intended to provide qualified virologist...
Other Medicine News:Health News:Launch Of India’s First Virology Course At Pun 2
...th the OLA2500 High Speed Sorter (HSS) system, ded...ements. As a front-end sample-processor, the OLA25...ample tubes to their destination racks quickly to...rrors. Post-analytical archiving to any archive ra...
COCOON Disposable Paediatric - Neonatal / Child
Bair Hugger® Model 536 - Pediatric Blanket Short
CareQuilt® Pediatric Warming Blanket
Medicine Products: